rAAVen Therapeutics

rAAVen Therapeutics is a Stockholm-based biotech developing a proprietary platform for engineering novel AAV capsids to overcome key limitations in gene therapy delivery, such as off-target effects and immunogenicity. The company's rAAptr platform integrates rational peptide design inspired by evolutionary biology with DNA barcoding and NGS to discover capsids with tailored tropism for diverse tissues. Operating as a platform and partnering company, rAAVen is pre-revenue and actively seeking collaborations with biotech and pharma partners to advance capsids for specific therapeutic programs. Its technology holds promise for improving the precision and efficacy of gene therapies across multiple organ systems.

The rAAptr platform integrates rational peptide design (inspired by evolutionary analysis of 600+ species), barcoded AAV library construction, in vivo screening, and next-generation sequencing to discover and optimize AAV capsids with precise tropism for specific cell types and tissues.

rAAVen competes in a crowded field of AAV engineering companies using various approaches, including directed evolution (e.g., Dyno Therapeutics, 4D Molecular Therapeutics), machine learning (e.g., Paratus Sciences), and synthetic biology. Its differentiation lies in its evolution-inspired rational design philosophy combined with high-throughput barcoded screening.